Viome Raises $54M to Advance mRNA Platform for Diagnosis, Drug Development

Original from: Genomeweb

Viome Life Sciences said Wednesday that it has raised $54M in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over $125M in total.

Returning investors in the pre-series C financing included Khosla Ventures, West River Group, Glico, Physician Partners, and Bold Capital Group. Ocgrow Ventures also participated as a new investor and Viome said Harish Consul, Ocgrow's founder and CEO will consequently serve as an observer on its board of directors.

Source: Viome Raises $54M to Advance mRNA Platform for Diagnosis, Drug Development